Articles tagged with Breast Cancer Cells
Recent findings by scientists at Lawrence Berkeley National Laboratory and University of California, San Francisco, reveal telomere crisis as a key event in breast cancer progression. The researchers found that telomere length decreases in hyperplasia, carcinoma in situ, and invasive cancers, indicating increased genomic instability.
A new study reveals surprising differences in the DNA of normal cells from different people, detecting 76 large-scale 'copy number polymorphisms' associated with various health conditions. The researchers used a powerful new DNA profiling technique called ROMA, which identified genes involved in neurological development and cancer.
Accelerated partial breast irradiation (APBI), also known as brachytherapy, treats breast cancer with minimal radiation exposure. This technique reduces treatment time to four to five days and improves convenience for women with busy lifestyles or rural locations.
A new method, QM-MSP, detects cancer by analyzing methylation levels in genes associated with breast cancer. The test was found to accurately identify cancerous samples in 84% of cases and detect no cancer in 89% of normal tissues.
Researchers found genes in stromal cells were overactive in early and late-stage breast cancer specimens. Targeting these components with cancer drugs might improve treatment effectiveness. The study identified two potential therapeutic targets: CXCL12 and CXCL14.
Researchers developed a novel vaccine by fusing patients' tumor cells with their immune system dendritic cells, resulting in increased T cell response against tumor cells. The treatment showed promise in reducing tumor growth and metastasis in late-stage cancer patients, with some experiencing significant regression of tumors.
Researchers discover that cancer cells misuse the Twist protein to bypass multiple steps of metastasis, a process that requires cell invasion and migration. The study suggests potential applications for developing a Twist inhibitor as a therapeutic approach.
A study found that targeting the Pak1-DLC1 interaction can prevent breast cancer growth. The researchers discovered that when DLC1 is modified, it interferes with cell death signals, allowing cancer cells to survive and multiply.
Researchers at UNC have identified a crucial role for a segment of Focal Adhesion Kinase (FAK) in activating the enzyme, which promotes cancer cell growth and metastasis. By making subtle changes to this region, they created a mutant protein that blocks FAK activity, suggesting potential therapeutic applications.
A Clemson researcher has received a grant from the Komen Foundation to further study the combination of a mutated prolactin receptor antagonist (PRL antagonist) and Herceptin, a breast cancer drug. The goal is to develop an effective treatment for aggressive subtypes of breast cancer.
A recent study by Merrill and colleagues found that soy GlcCer, a type of sphingolipid, can reduce the number of tumors in mice with colon cancer. The study's results suggest that consuming soybeans may help prevent colon cancer by targeting beta-catenin, a protein involved in cell growth.
A study found that women with core breast biopsy results showing minimal abnormal cells were still at risk of having cancer when surgical excision was performed. The study suggests that these women should undergo surgical excision to ensure accurate cancer detection.
A new study separates and purifies normal luminal and myoepithelial cells from breast tissue, revealing distinct gene expression profiles. This dataset enables the discrimination between genetic changes due to cell type differences and cancer, leading to more accurate tumor classification and potential new therapeutic avenues.
Researchers found that three polyphenolic compounds, EGCG, XN, and RES, can reduce breast cancer cell proliferation without being toxic. Xanthohumol (XN) showed the most potent effect, with a lower concentration required to inhibit cell growth.
Researchers found that hormone-sensitizing compounds can boost estrogen and progestin activity eight- to 10-fold, increasing cancer risk. Exposure to these compounds may be linked to reproductive toxicity, miscarriages, and irregular ovulation.
Dr. Bissell's research reveals that the cellular microenvironment plays a crucial role in gene expression and cell behavior. She discovered that malignant cells can be reverted to a normal phenotype through manipulation of the extracellular matrix.
Researchers at MIT have developed a technique that uses focused microwave energy to kill early-stage breast cancer cells, reducing the need for additional surgery. The treatment has shown promising results, with women experiencing a 43% reduction in cancer cells found close to surgical margins.
The study found that 97.5% of patients with DCIS underwent surgery, but there is a wide variation in treatment approaches, including the use of mastectomy, radiation therapy, and axillary dissection. The incidence of DCIS increased by 73% between 1992 and 1999, highlighting the need for standardized treatment recommendations.
A team of researchers has identified a protein called APC that regulates cell growth and limits the development of cancer. By controlling the levels of another protein Skp2, APC helps prevent cancer cells from growing uncontrollably.
The American Association for Cancer Research (AACR) has awarded scholarships to 91 minority and underrepresented scientists participating in its Annual Meeting. The AACR offers several award programs, including the Minority Scholar Awards, which support early-career scientists from traditionally underrepresented groups.
A widely used anti-nausea drug, dexamethasone, may interfere with cancer chemotherapy. Pretreatment with dexamethasone reduces the ability of paclitaxel and doxorubicin to kill cancer cells by upregulating genes that protect breast cancer cells from cell death.
A new vaccine has been shown to halt HER-2/neu preneoplastic breast cancer lesions through both morphologic and gene expression data. The findings suggest a potential breakthrough in the treatment of this type of cancer, according to a recent study published in JCI Journals.
Researchers discover IGF-1R inhibition significantly impacts tumor cell growth and sensitivity to chemotherapy, highlighting its potential as an anticancer therapeutic. Two selective inhibitors of IGF-1R are identified with potent antitumor activity against multiple myeloma and other hematological malignancies.
Researchers found that elevated levels of protein MUC1 in human tumors reduce apoptosis signals and confer resistance to anticancer agents. Reducing MUC1 increases sensitivity to these drugs, suggesting it as a potential target for future cancer therapeutics.
Researchers at Mayo Clinic discovered a crucial link between the cancer gene CBP and protein p27Kip1 in the development of lymphoma, breast and colon cancers. The study found that the absence of CBP and low levels of p27Kip1 accelerate cancer growth in laboratory mice.
Researchers have discovered that protein cdk6 inhibits breast cancer cell growth, suggesting a promising avenue for diagnosis and treatment. Cdk6 levels were found to be significantly lower in breast cancer cells compared to normal cells, with increased expression of cdk6 linked to suppressed cell growth.
A new theory by Steven Frank proposes that cancer progression speeds up with age, leading to increased incidence in older adults. As people age, fewer stages remain before cancer develops, resulting in higher cancer rates.
Researchers at the University of Iowa have identified a new mode of action for tamoxifen, an anti-estrogen medication used to treat breast cancer. Tamoxifen turns on the tumor suppressor gene maspin, which inhibits tumor invasion and metastasis in normal breast cells.
Researchers found that oral drug ZD1839 suppressed the growth of ER-negative breast cancer cells and delayed the formation of tumors in transgenic mice. The treatment also reduced proliferation of normal breast cells by 20.3% and tumor cells by 42%. However, long-term safety data are needed for further research.
The new device detects subtle changes in cells before tumor formation, enabling early detection and potentially improved treatment outcomes. It can image small breasts and axillary lymph nodes, and works without breast compression, making it more comfortable for patients.
Researchers developed a magnetic resonance spectroscopy method to quantify choline levels in breast tissue, distinguishing malignant lesions from benign lumps. The technique uses high magnetic fields and mathematical approach to account for tissue variations.
Researchers discovered two new proteins, BRCC36 and RCC45, that are part of the BRCC complex and linked to sporadic breast cancers. The complex regulates DNA repair and cell division, influencing cancer susceptibility.
Researchers successfully grew breast cancer tissue from human and mouse mammary stem cells, paving the way for new treatments. The findings aim to overcome drug resistance and relapse in breast cancer patients, with potential to transform cancer treatment.
Case Western Reserve University scientists identified a protein called clusterin that can signal cell distress and detect cancer. A simple blood test could potentially identify abnormal clusterin levels, indicating the presence of cancer.
A USC study found that physical activity can reduce the risk of breast carcinoma in situ (BCIS) by up to 35%, particularly among women who exercise more than four hours a week. The exact mechanism is unclear, but hormones and immune-boosting effects are potential theories.
A new treatment approach uses a Trojan Horse technique to deliver a radioactive isotope into breast cancer cells, slowing tumour growth. The therapy combines EGF with Indium-111, exploiting the natural uptake of EGF by breast cancer cells.
A new study has found that the protein EZH2 is linked to aggressive and deadly breast tumors, with higher levels corresponding to worse patient outcomes. The discovery may lead to a new test for determining breast cancer prognosis more precisely.
Researchers discover dermcidin protein in 10% of invasive breast tumors, contributing to faster cell growth and cachexia. The finding may lead to new treatments for breast cancer and conditions like Alzheimer's disease.
Scientists at Wake Forest are studying the genetic defects that allow cancer cells to resist cell death, in hopes of developing new treatments. They will use normal cells converted into cancer cells through controlled mutations to understand how resistance occurs.
Researchers at UIC College of Medicine identified 57 genes involved in cell proliferation, including some not previously known to play a role in cancer cell growth. The study found that certain fragments inhibited the multiplication of breast cancer cells by shutting down genes necessary for cell growth.
A new study suggests that telomere dysfunction may play a causal role in human intraepithelial neoplasia (IEN) found in precancers. Short telomeres were found in the majority of precursor lesions across various types of cancers, indicating potential early molecular mechanisms underlying cancer development.
Researchers found that the normal form of the BRCA-2 gene enhances androgen receptors' activity to suppress tumors. The mutant form of BRCA-2 fails to enhance activity, allowing cancer cells to proliferate. The study provides new insights into male breast cancer and its connection to the BRCA-2 gene.
Researchers have identified a set of genes specifically associated with breast cancer's ability to metastasize to bone. The study found that these 'poor prognosis signature' genes enable tumor cells to home in on bone and trigger growth of blood vessels. The discovery does not invalidate the classical model of tumor cell metastasis, bu...
Researchers discovered that four peptide hormones from the heart inhibited DNA synthesis and tumor cell growth in laboratory tests, outperforming a standard drug used to treat pancreatic cancer. The findings suggest these naturally-occurring hormones may hold promise as an alternative treatment option with fewer side effects.
A study by Temple University researchers found that pRb2/p130 binds to the estrogen receptor alpha and recruits molecules that make breast tumors more responsive to treatment. However, mutated pRb2/p130 signals can silence the expression of the estrogen receptor, making therapies less effective against cancer cells.
Bruce Lipshutz's patented method uses transition metal catalysts to produce CoQ10 efficiently, targeting cancer, Parkinson's, and Huntington's diseases. The process reduces costs by using inexpensive ingredients and minimizing production steps.
Researchers found a slight benefit of allogeneic stem cell transplantation in patients with metastatic breast cancer, experiencing delayed tumor progression despite poor prognosis. The study's findings suggest a potential
A Phase II study shows that administering ADVEXIN, a p53 drug, directly to tumors can improve the results of neoadjuvant chemotherapy in locally advanced breast cancer. The treatment resulted in dramatic tumor shrinkage and minimal residual tumor cells.
Prolactin's role in breast cancer has been redefined with the discovery of its ability to travel directly into cell DNA. This finding suggests a new paradigm for hormone function and offers potential therapies for blocking tumor growth.
The study identified a new gene associated with breast cancer, C35, which is over-expressed in 65% of breast cancers. Researchers believe that traditional treatment methods alone will not be effective against C35 positive breast cancer and are exploring a two-pronged approach for treatment.
The discovery of KCNK9 reveals a significant role in the development of breast and lung cancers. The study found that overexpression of KCNK9 promotes tumor formation in controlled functional tests.
Researchers found that women with high levels of AIB1 and HER-2 proteins in their tumors are more likely to experience poor outcomes with tamoxifen therapy. When either protein level is low, the risk of adverse effects decreases significantly.
Researchers have identified stem cells in human breast cancer that can form new tumors and are resistant to treatment. The discovery may explain why current treatments for metastatic breast cancer often fail, and could lead to the development of new therapies targeted at these cells.
Researchers at Cornell University aim to learn how enzymes modify estrogen receptors, potentially leading to better diagnostic and therapeutic options for breast cancer patients. The study aims to clarify the molecular details of the estrogen-signaling pathway in normal and diseased tissues.
Researchers have discovered a new genetic mechanism to prevent cancer development by targeting the Cdk4 gene. The study showed that knocking out this gene can make cells resistant to cancer even if their tumor suppressor defense is deficient. Cells then enter senescence, offering a promising new option for cancer therapy.
Researchers have found that Cdk4 expression is essential for Ras-induced cancer development, making it a potential target for therapy. Dr. Hiroaki Kiyokawa and colleagues showed that Cdk4-deficient cells can enter a protective state of senescence when exposed to oncogenes like Ras.
A recent study found that high levels of cyclin E are closely associated with aggressive breast cancer, making it a powerful predictive marker. The presence of low molecular weight forms of cyclin E also showed strong prognostic value, indicating a higher risk of recurrence and spread.
Researchers used precancerous breast cells from patients with Li-Fraumeni syndrome to test the effectiveness of chemopreventive agents in preventing cancer. Treatment with tamoxifen, a p53-rescue drug, and PPAR-ã agonist showed promise in stopping cancer development, suggesting new potential therapies for high-risk individuals.
Researchers discovered deguelin's ability to selectively block the growth of precancerous and cancerous human bronchial epithelial cells. The study suggests deguelin may inhibit Akt activation, a critical cell survival signal for tumor progression.
Researchers investigate potential link between low-level exposure to zeranol and breast cancer risk. The study explores the biological effects of zeranol, a synthetic non-steroidal agent used in cattle feed, on human breast tissue.